Biote Corp. reported third quarter 2026 revenue of $43.3 million, significantly missing analyst estimates of $53.8 million as the recovery in core procedure volume progressed slower than anticipated. Despite the top-line miss, the company achieved a surprise GAAP profit of $0.01 per share compared to expected losses, while maintaining its full-year 2026 financial outlook.
Key Highlights
- Procedure-related revenue declined 15.1% year-over-year to $28.9 million, missing consensus estimates of $48.2 million by nearly 40%.
- Gross margins contracted 410 basis points to 67.7% due to residual impacts from a January 2026 product recall and the resulting reliance on lower-margin third-party pellet suppliers.
- Adjusted EBITDA fell 60.5% to $5.1 million from $12.9 million in the prior-year period, driven by lower volume and compressed margins.
- Dietary supplement revenue grew 7.3% to $12.0 million, providing a modest offset to the decline in the core hormone procedure business.